Part Used : ใบ
Activity : EFFECTS ON PHARMACOKINETIC
Solvent/Active Compound : Ginkgo biloba extract (GBE)
Type of experiment : human
Type of animal : -
Type of study : Open trial
N(Total) : 40
N(Treatment) : 40
Route : Oral administration
Dose/Conc.(herb) : Two 60-mg capsules taken twice daily
Duration : 14 days
Type of interaction : Pharmacokinetics
Interaction with drug : Bupropion
Dose/Conc.(drug) : -
Remark : *Age: mean 21.3+/-1.4 yrs, range 19-25 yrs
GBE administration resulted in no significant effects on the AUC0-infinity value of bupropion and hydroxybupropion. Bupropion mean AUC0-infinity value was 1.4 microgram.h/ml-1 (95% Cl 1.2, 1.6) prior to GBE treatment and 1.2 microgram.h/ml-1 (95% Cl 1.1, 1.4) after 14 days of treatment. Hydroxybupropion mean AUC0-infinity value was 8.2 microgram.h/ml (95% Cl 6.5, 10.4) before GBE administration and 8.7 microgram.h/ml (95% Cl 7.1, 10.6) after treatment. The Cmax of hydroxybupropion increased from 221.8 nanogram/ml (95% Cl 176.6, 278.6) to 272.7 nanogram/ml (95% Cl 215.0, 345.8) (p=0.038) and the t1/2 of hydroxybupropion fell from 25.0 h (95% Cl 22.7, 27.5) to 21.9 h (95% Cl 19.9, 24.1) (p=0.000).
Note : - Healthy volunteers.
- After an overnight fast, volunteers ingested a single oral dose of 150 mg sustained-release bupropion with water (150 ml). Blood samples for pharmacokinetic analysis were taken for 3 days post dose. Following a wash-out period of at least 7 days, volunteers took two 60-mg capsules (120 mg) of G. biloba twice daily for 14 days. On day 15, a single 15-mg oral dose of bupropion was then administered after overnight fasting.
- The GBE, containing a minimum of 24% ginkgo flavones glycosides and 6% terpene lactone.
